A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab
Patients who received NIVO+IPI with NIVO maintenance and patients who had undergone prior nephrectomy experienced the most favorable survival outcomes, aligning with results from previous studies.
Authors
- Poonam Dhokia
- Lisa M. Pickering (ORCID: https://orcid.org/0000-0002-7579-340X)
- Debbie Scott (ORCID: https://orcid.org/0000-0002-4530-584X)
- Matthew Wheater (ORCID: https://orcid.org/0000-0001-6561-5290)
- T. Geldart (ORCID: https://orcid.org/0000-0001-6413-5789)
- Martin Hale (ORCID: https://orcid.org/0000-0002-5326-9762)
- Anand Sharma (ORCID: https://orcid.org/0000-0003-4161-9398)
- Stacey J. Coleman
- Omi Parikh (ORCID: https://orcid.org/0000-0003-4181-7124)
- Luis R. Vaz (ORCID: https://orcid.org/0000-0002-2184-1234)
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- Poole Hospital (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- Mount Vernon Cancer Centre (GB)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Bristol-Myers Squibb (Italy) (IT)
- Royal Preston Hospital (GB)
- University Hospitals Dorset NHS Foundation Trust
Publication Details
- Journal
- Future Oncology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1080/14796694.2025.2595686
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00